Clinical potential of brodalumab in the management of psoriasis: the evidence to date

Brodalumab is an anti-IL-17 receptor monoclonal antibody currently in development for the treatment of moderate-to-severe plaque psoriasis. With many systemic psoriasis therapies to choose from, and several newer agents in development, physicians need up to date evidence for the use of these drugs....

Descripción completa

Detalles Bibliográficos
Autores principales: Sandoval, Laura F, Williams, Brooke, Feldman, Steven R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683110/
https://www.ncbi.nlm.nih.gov/pubmed/29387580
http://dx.doi.org/10.2147/PTT.S49996

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683110/
https://www.ncbi.nlm.nih.gov/pubmed/29387580
http://dx.doi.org/10.2147/PTT.S49996

Ejemplares similares